Media Doctor Canada
Follow us on Twitter








"New drugs extend life of renal cancer victims"

Edmonton Journal

Source: Edmonton Journal

Published: 12 Jan 2022

Category: Pharmaceutical

Rating: (2½ stars)

what they said (Hover the mouse cursor over underlined words for more info)

WASHINGTON - Two new treatments doubled the life expectancy of people afflicted with advanced cases of the very common cancer of the kidney, said studies published this week in the United States.

The two medicines belong to a new breed of auspicious cancer treatments that inhibit angiogenesis, the development of blood vessels that feed tumours.

The studies appeared in the Jan. 11 edition of the New England Journal of Medicine...

The original article can be found at:

how did it rate? (more information)

Criteria Rating
Total Score 5 of 10
Availability of Treatment Not Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Satisfactory (?)
Quantification of Benefits of Treatment Satisfactory (?)
Harms of Treatment Not Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of Harms of Treatment Not Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

Sunitinib and sorafenib which belong to a new class of agents that are being studied in patients with advanced cancer of the kidney. It appears that these agents do, on average, increase the life span by 3-6 months, but unfortunately, the article provides no information on side effects, cost, or availability of these agents - information clearly required to help consumers make an informed decision.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada